Clinical trial
A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)
NCT02722304 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Baxalta now part of Shire
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 2, 2016
- Completion date
- September 14, 2018
- Enrollment
- 7 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
alpha1-antitrypsin deficiency, chronic obstructive pulmonary disease